

# Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

## Roche: Cobas 6000 analyzer

RRID:SCR\_023262

Type: Tool

---

### Proper Citation

Roche: Cobas 6000 analyzer (RRID:SCR\_023262)

---

### Resource Information

**URL:** <https://diagnostics.roche.com/us/en/products/systems/cobas-6000-analyzer-series-sys-65.html>

**Proper Citation:** Roche: Cobas 6000 analyzer (RRID:SCR\_023262)

**Description:** Roche/Hitachi Cobas 6000 analyzer series is fully automated, random-access, software- controlled system for immunoassay and photometric analyses intended for qualitative and quantitative in vitro determinations of wide variety of tests. Cobas 6000 modular analyzer is composed of core unit and combination of up to 3 analytical modules to best suit your needs.

**Synonyms:** , Roche COBAS 6000 analyzer automated system, Roche/Hitachi Cobas 6000 analyzer series, COBAS 6000 analyzer automated system

**Resource Type:** instrument resource

**Keywords:** Roche, Hitachi, Cobas analyzer system, automated system, immunoassay and photometric analyses, instrument, equipment, USEDit

**Resource Name:** Roche: Cobas 6000 analyzer

**Resource ID:** SCR\_023262

**Record Creation Time:** 20230209T050202+0000

**Record Last Update:** 20260801T190752+0000

---

### Ratings and Alerts

No rating or validation information has been found for Roche: Cobas 6000 analyzer.

No alerts have been found for Roche: Cobas 6000 analyzer.

---

### Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Kaaks R, et al. (2025) A Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer - Baseline Findings for CA125. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(12), 2441.

Behairy N, et al. (2024) Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer. The Journal of clinical endocrinology and metabolism.

Jallouli S, et al. (2024) 12-week melatonin intake attenuates cardiac autonomic dysfunction and oxidative stress in multiple sclerosis patients: a randomized controlled trial. Metabolic brain disease, 40(1), 52.